Physician profile
Daniel Vergara
NPI 1316444045
$304.68
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.48 · 2020: $27.78 · 2021: $79.32 · 2022: $166 · 2023: $18.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2022 | |
| Novo Nordisk INC | $64.62 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.71 | 2022 | |
| Glaxosmithkline, LLC. | $18.39 | 2023 | Shingrix, Bexsero |
| Lilly USA, LLC | $17.16 | 2021 | |
| Travere Therapeutics, INC. | $13.48 | 2019 | |
| Hikma Pharmaceuticals USA | $12.66 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Vergara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.